Severe Covid-19

Patients with severe Covid-19 should have close monitoring for the need for endotracheal intubation; intubated patients should receive lung-protective ventilation. Data from randomized, controlled trials support a reduction in mortality with the use of dexamethasone and a reduction in time to clinic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-12, Vol.383 (25), p.2451-2460
Hauptverfasser:	Berlin, David A, Gulick, Roy M, Martinez, Fernando J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - analogs & derivatives Alanine - therapeutic use Anti-Inflammatory Agents - therapeutic use Antiviral Agents - therapeutic use Antiviral drugs Brain - diagnostic imaging Clinical trials Coronaviruses COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 - therapy COVID-19 Testing Dexamethasone Dexamethasone - therapeutic use Dyspnea Dyspnea - etiology Edema Failure General & Internal Medicine Humans Hypoxemia Illnesses Infections Intubation Life Sciences & Biomedicine Lung - diagnostic imaging Lung - pathology Male Masks Mechanical ventilation Medical supplies Medicine, General & Internal Middle Aged Oxygen saturation Pandemics Patient Acuity Patients Personal protective equipment Radiography, Thoracic Renal failure Respiration, Artificial Respiratory distress syndrome Respiratory Distress Syndrome - etiology Respiratory Distress Syndrome - therapy SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification Science & Technology Severe acute respiratory syndrome coronavirus 2 Thrombosis Tomography, X-Ray Computed Ventilators
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with severe Covid-19 should have close monitoring for the need for endotracheal intubation; intubated patients should receive lung-protective ventilation. Data from randomized, controlled trials support a reduction in mortality with the use of dexamethasone and a reduction in time to clinical recovery with the use of remdesivir.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMcp2009575